Company Focuses on Simplicity and Quality in Advancing Rapid Platform
HALIFAX, March 13 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF), a global market leader in premium rapid diagnostic solutions,
announced today that it has filed a patent application with the United States
Patent Office for its new rapid test platform. MedMira's research &
development team has been working on a next generation, rapid test based on
the company's patented flow-through diagnostic technology. This next
generation rapid test is built on the key quality and performance attributes
that have enabled MedMira's rapid HIV and HIV/Hepatitis combination tests to
obtain regulatory approvals from the most stringent regulatory authorities in
the world, including United States, Canada, China, India, Russia, and Europe.
"Our new test platform provides the user with an even simpler,
user-friendly testing procedure than we currently offer in our rapid tests,
without sacrificing the high quality and consistent performance that MedMira
has built its reputation on," said Dr. Neeraj Vats, Vice President of
Technology & Intellectual Property, MedMira Inc. "The new test platform makes
it possible to perform a rapid, flow-through test in just two easy steps, and
exhibits the high sensitivity and specificity for which MedMira tests are
known the world over."
Dr. Vats continued, "Our new rapid test platform will have broad
applications across a wide range of diagnostic fields, including the diagnosis
of infectious diseases such as HIV, hepatitis, and influenza, as well as new
health epidemics that will emerge in the future. The platform will also be
able to aid in the diagnosis or monitoring of non-infectious conditions such
as cancer and cardiovascular disease."
As healthcare providers and public health authorities around the world
take greater steps to combat epidemics like HIV and Hepatitis, the demand for
advanced rapid tests will continue to grow. MedMira's rapid tests are designed
for performance in any type of testing setting, from the laboratory to point
of care to consumer products for self-testing. While healthcare budgets and
resources are constantly under pressure, and with self-testing becoming
accepted in various markets; MedMira will be ready to meet the growing demand
with this next generation rapid test platform.
"MedMira is built on innovation and its ability to understand the future
needs of healthcare providers and patients. As market demands increase for
consumer products for self-testing, MedMira will be ready with this next
generation test, placing the power of rapid testing in the hands of patients,
enabling them to monitor and maintain their health wherever and whenever it is
most convenient and comfortable," said Dr. Vats.
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals around the world with reliable, rapid diagnosis for diseases such
as HIV and hepatitis C in just three minutes. The company's tests are sold
under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in
global markets. MedMira's rapid HIV test is the only one in the world to
achieve regulatory approvals in Canada, the United States, China and the
In January 2006, MedMira launched the Maple Biosciences division to
develop and commercialize diagnostic instruments based on two revolutionary
biosensor-based technology platforms. The solutions developed by Maple
Biosciences will enable routine laboratory tests to be performed in a matter
of minutes, increasing laboratory automation, streamlining the diagnosis of
multiple conditions and diseases and positioning MedMira to be a leading
participant in the emerging fields of personalized medicine and molecular
diagnostics. For more information visit www.maplebio.com.
MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada with a representative office in China. Maples
Biosciences' labs are located in Toronto, Ontario. For more information visit
MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
For further information:
For further information: Dr. James Smith, Investor Relations & Corporate
Affairs, (902) 450-1588, email@example.com